Inhibrx Biosciences, Inc. INBX
90.59 USD -0.02 (-0.02%)
At closeNov 11, 2026, 4:00 PM EST
91.10 +0.51 +0.56%
After hours · Nov 11, 4:00 PM ET
89.39 Day range 93.48
57.30 52-week range 155.29
- YTD
- +14.67%
- 1 year
- +16.38%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
defenseworld.net Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.47 and traded…
prnewswire.com Inhibrx Announces Participation in Upcoming Scientific Conferences SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of…
defenseworld.net Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
marketbeat.com Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical…
defenseworld.net Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) rose 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last…
defenseworld.net Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price was up 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as…
defenseworld.net Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The stock was purchased…
defenseworld.net Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was purchased…
fool.com Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held…
seekingalpha.com Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106 Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma…
seekingalpha.com Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk…
benzinga.com Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.
benzinga.com Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
reuters.com Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
prnewswire.com Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with…
benzinga.com Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT – Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage
prnewswire.com Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study – Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
benzinga.com HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245 HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
prnewswire.com Inhibrx Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical…
seekingalpha.com Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027…
prnewswire.com Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic…
zacks.com Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027 No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic…
prnewswire.com Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic…
benzinga.com Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the analyst consensus estimate of $(1.79) by 20.11 percent. This is a 23.21 percent increase over losses…
benzinga.com Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.
benzinga.com Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC Today, the Company presented preliminary data from 53 patients (25 in the INBRX-106 combination arm and 28 in the control arm) with a data cutoff of May 7, 2026, representing the evaluable population…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast – Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage…
benzinga.com Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares rose 14.1% after beating estimates and raising sales guidance.
benzinga.com Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69%. Utilities sector jumps 1.4%, financials only up 0.1%.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/- benzinga.com Inhibrx Announces Updated Interim Data From Phase1/2 Ozekibart Combination With Folfiri Evaluation Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC. The Company also plans to…
benzinga.com This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.- benzinga.com Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150 Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Earnings Scheduled For November 14, 2025 
benzinga.com Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday? Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October 
benzinga.com Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying